Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Recent clinical, regulatory, research and industry developments relating to this disease.
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Hematologic Neoplasms1
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma1
Leading journals2
- Blood1
- Science translational medicine1
Leading researchers8
- Arber DA1
- Bloomfield CD1
- Borowitz MJ1
- Cazzola M1
- Engel NW1
- Garcia KC1
- Gill SI1
- Gonzales D1
Affiliations (unnormalised)6
- Center for Cellular Immunotherapies1
- Comprehensive Cancer Center1
- Department of Pathology and Laboratory Medicine1
- Howard Hughes Medical Institute1
- Institute of Pathology1
- John Hopkins Medical Institutions1
Reference
Authoritative identity, definition & identifiers.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.